Global Perspective on BRCA Mutations, PARPi, and Biomarker-Driven Strategies in Pancreatic Cancer

Global Perspective on BRCA Mutations, PARPi, and Biomarker-Driven Strategies in Pancreatic Cancer

Tuesday, September 8, 2020
Webinar -- 12:00 PM ET


  • Overview of BRCA, DDR, and Homologous Recombination in Pancreatic Cancer – Dr. Pishvaian 
    • The concept of BRCAness as a homologous recombination deficiency
    • Germline vs somatic mutations in DDR genes
    • Synthetic lethality and mechanism of action of PARP inhibitors
  • Molecular Testing Considerations for Patients with Pancreatic Cancer – Dr. Pishvaian
    • Clinical rationale behind the testing
    • In which patient population testing should be considered
  • Existing Data on Treatment of Patients with BRCA – Dr. Arnold
    • Available clinical data from clinical trials
    • Platinum-based chemotherapy in patients with germline-mutated PDAC
    • Adverse event profiles
  • Ongoing Clinical Trials and Combination Strategies in PDAC With Germline or Somatic DNA Damage Repair Mutations – Dr. Arnold
    • Ongoing PARP inhibitor monotherapy trials
    • PARP inhibitors in synergistic combinations to improve efficacy and reduce resistance to individual agents


Dirk Arnold, MD, PhD

Professor of Medicine
University Hamburg  

Asklepios Tumorzentrum Hamburg 

Head of Department
Oncology, Hematology and Rheumatology
AK Altona
Paul-Ehrlich-Strasse 1
22763 Hamburg

Michael J. Pishvaian, MD

Associate Professor, Department of Oncology
Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
5255 Loughboro Rd NW, Washington, DC 20016, USA

Goal Statement
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with pancreatic cancer.

Target Audience
This program is intended for medical oncologists and other healthcare providers who care for patients with pancreatic cancer globally.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the clinical rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer
  • Plan therapeutic strategies for patients with pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Examine the emerging role of PARP inhibitors in the frontline maintenance setting for patients with BRCA-mutant pancreatic cancer
  • Discuss the rationale for using platinum-based chemotherapy in patients newly diagnosed pancreatic cancer and germline BRCA mutations, based on available data and treatment guidelines